R
R. Lor Randall
Researcher at University of California, Davis
Publications - 208
Citations - 7743
R. Lor Randall is an academic researcher from University of California, Davis. The author has contributed to research in topics: Sarcoma & Medicine. The author has an hindex of 35, co-authored 180 publications receiving 6228 citations. Previous affiliations of R. Lor Randall include Primary Children's Hospital & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren,R. Lor Randall,Robert S. Benjamin,Sarah Boles,Marilyn M. Bui,Ernest U. Conrad,Kristen N. Ganjoo,Suzanne George,Ricardo J. Gonzalez,Martin J. Heslin,John M. Kane,Henry B. Koon,Joel L. Mayerson,Martin D. McCarter,Sean V. McGarry,Christian F. Meyer,Richard J. O'Donnell,Alberto S. Pappo,I. Benjamin Paz,Ivy A. Petersen,John D. Pfeifer,Richard F. Riedel,Scott M. Schuetze,Karen D. Schupak,Herbert S. Schwartz,William D. Tap,Jeffrey D. Wayne,Mary Anne Bergman,Jillian L. Scavone +28 more
TL;DR: This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
Journal ArticleDOI
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
Yoko S. DeRose,Guoying Wang,Yi Chun Lin,Philip S. Bernard,Saundra S. Buys,Mark T. W. Ebbert,Rachel E. Factor,Cindy B. Matsen,Brett Milash,Edward W. Nelson,Leigh Neumayer,R. Lor Randall,Inge J. Stijleman,Bryan E. Welm,Alana L. Welm +14 more
TL;DR: It is reported that tumor engraftment is a prognostic indicator of disease outcome for women with newly diagnosed breast cancer and orthotopic breast tumor grafting is a step toward individualized models for tumor growth, metastasis and prognosis.
Journal ArticleDOI
Soft Tissue Sarcoma
George D. Demetri,Scott Antonia,Robert S. Benjamin,Marilyn M. Bui,Ephraim S. Casper,Ernest U. Conrad,Thomas F. DeLaney,Kristen N. Ganjoo,Martin J. Heslin,Raymond J. Hutchinson,John M. Kane,G. Douglas Letson,Sean V. McGarry,Richard J. O'Donnell,I. Benjamin Paz,John D. Pfeifer,Raphael E. Pollock,R. Lor Randall,Richard F. Riedel,Karen D. Schupak,Herbert S. Schwartz,Katherine Thornton,Margaret von Mehren,Jeffrey D. Wayne +23 more
TL;DR: Soft-tissue sarcomas are a rare group of tumours comprising approximately 1% of all malignant tumours, and conventional management has relied heavily on surgery, but the inadequacy of this approach is reflected by local recurrence rates of 40%–80% in adult Sarcomas and of as high as 90% in childhood sarcoma.
Journal ArticleDOI
miRNA Signatures Associate with Pathogenesis and Progression of Osteosarcoma
Kevin B. Jones,Zaidoun Salah,Sara Del Mare,Marco Galasso,Eugenio Gaudio,Gerard J. Nuovo,Francesca Lovat,Kimberly T. LeBlanc,Jeff Palatini,R. Lor Randall,Stefano Volinia,Gary S. Stein,Carlo M. Croce,Jane B. Lian,Rami I. Aqeilan +14 more
TL;DR: A miRNA signature associated with pathogenesis of osteosarcoma as well as critical pre-treatment biomarkers of metastasis and responsiveness to therapy is established.
Journal ArticleDOI
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina,Sigbjørn Smeland,Stefan S. Bielack,Mark L. Bernstein,Gordana Jovic,Mark Krailo,Jane Hook,Jane Hook,Carola A.S. Arndt,Henk van den Berg,Bernadette Brennan,Bénédicte Brichard,Kenneth L.B. Brown,Trude Butterfass-Bahloul,Gabriele Calaminus,Heike E. Daldrup-Link,Mikael Eriksson,Mark C. Gebhardt,Hans Gelderblom,Joachim Gerss,Robert E. Goldsby,Allen M. Goorin,Richard Gorlick,Holcombe E. Grier,Juliet Hale,Kirsten Sundby Hall,Jendrik Hardes,Douglas S. Hawkins,Knut Helmke,Pancras C.W. Hogendoorn,Michael S. Isakoff,Katherine A. Janeway,Heribert Jürgens,Leo Kager,Thomas Kühne,Ching C. Lau,Patrick J. Leavey,Stephen L. Lessnick,Leo Mascarenhas,Paul A. Meyers,Hubert Mottl,Michaela Nathrath,Zsuzsanna Papai,R. Lor Randall,Peter Reichardt,Marleen Renard,Akmal Safwat,Cindy L. Schwartz,Michael C. Stevens,Sandra J. Strauss,Lisa A. Teot,Mathias Werner,Matthew R. Sydes,Jeremy Whelan +53 more
TL;DR: The EURAMOS-1 results do not support the addition of ifosfamide and etoposide in patients with poorly responding osteosarcoma, and the primary outcome measure was event-free survival measured in the intention-to-treat population.